ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2676

Long-Term Humoral Autoimmunity to Ro60 in Primary Sjögren’s Syndrome Is Driven by Clonal Succession

Rhianna Lindop1, Isabell Bastian1, Georgia Arentz1, Lauren Thurgood1, Andrew Whyte1, Tim, K. Chataway2, Michael Jackson1 and Tom Gordon1, 1Immunology, Flinders Medical Centre and Flinders University, Adelaide, Australia, 2Human Physiology, School of Medicine, Flinders University, Adelaide, Australia

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, autoimmune diseases and plasma cells, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome I - Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose : Long-lived humoral autoimmunity to Ro60 is considered a hallmark of primary Sjögren’s syndrome (SS), but the mechanism by which this immunity is sustained over decades remains unclear. Persistence of anti-Ro60 autoantibodies could be generated either by long-lived plasma cells residing in the bone marrow or by continual production of short-lived plasma cells. In the present study, these models were tested in humans for the first time by analysing serial molecular signatures of a recently reported public Ro60-specific clonotypic autoantibody (1).

Methods: Serial serum samples were collected over weeks to years from 8 patients with primary SS who expressed stable VH3-23/ VK3-20 Ro60 clonotypic autoantibody levels. Clonotypic IgGs were isolated by epitope-specific affinity chromatography and subjected to high resolution Orbitrap mass spectrometry. Variable regions of heavy and light chains were analysed by combined database and de novoamino acid sequencing. Alterations in autoantibody affinity were assessed by equilibrium binding analysis (Biacore).

Results: At each time point, patients expressed a single Ro60-specific monoclonal IgG1 kappa species, specified by a VH3-23/JH5 and VK3-20/JK2 pairing signature. However, near full-length V region protein sequencing showed a subtle turnover of clonotypes that was not detected by solid-phase immunoassay. The clonal turnover was characterised by 4-6 month cycles of clonal succession, with dominant clonotypes undergoing continual replacement by new somatically mutated clonal variants. Surprisingly, earlier clones never reappear in the periphery, and each new clone has a unique molecular signature. Affinities (KD value) of successive clonotypes did not change significantly in the face of ongoing perpetual turnover. Autoantibody levels showed a cyclical rise and fall pattern every 3-4 months in keeping with this turnover model.

Conclusion: Analysis of the secreted autoantibody proteome demonstrates a dynamic process of clonal succession that masquerades as long-term Ro60 humoral autoimmunity. Surprisingly, the selection pressure for replacement clones is not based on affinity selection, indicating that an affinity ceiling is reached early in disease.  Our findings are compatible with ongoing clonal expansion and exhaustion of short-lived autoreactive plasma cells, as opposed to a single event generation of long-lived plasma cells. The relentless generation of autoantibody clonotypes in primary SS by antigen-driven clonal selection has important therapeutic and diagnostic implications.

(1) Lindop et al. (2011), Arthritis Rheum, Vol. 63, No. 11, p.p. 3477-3486.


Disclosure:

R. Lindop,
None;

I. Bastian,
None;

G. Arentz,
None;

L. Thurgood,
None;

A. Whyte,
None;

T. K. Chataway,
None;

M. Jackson,
None;

T. Gordon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-humoral-autoimmunity-to-ro60-in-primary-sjogrens-syndrome-is-driven-by-clonal-succession/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology